<DOC>
	<DOCNO>NCT00655785</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability HLA-A*2402 restrict epitope peptide VEGFR1 VEGFR2 emulsify Montanide ISA 51 combination gemcitabine</brief_summary>
	<brief_title>Antiangiogenic Peptide Vaccine Therapy With Gemcitabine Treating Patient With Pancreatic Cancer ( Phase1/2 )</brief_title>
	<detailed_description>Vascular endothelial growth factor receptor 1 2 ( VEGFR1 andVEGFR2 ) essential target tumor angiogenesis , identify peptide derive receptor significantly induce effective tumor specific CTL response vitro vivo . According finding , trial , evaluate safety , tolerability immune response peptide emulsify Montanide ISA 51 combination gemcitabine</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS 1 . Locally advanced metastatic pancreatic cancer preclude curative surgical resection recurrent pancreatic cancer 2 . Measurable disease CT scan PATIENTS CHARACTERISTICS 1 . ECOG performance status 02 2 . Life expectancy &gt; 3 month 3 . Laboratory value follow : 2,000/mm3 &lt; WBC &lt; 15000/mm3 Platelet count ≥ 750,000/mm³ Total Bilirubin ≤ 1.5 x Aspartate transaminase &lt; 150 IU/L Alanine transaminase &lt; 150 IU/L Creatinine ≤ 3.0 mg/dl 4 . HLAA*2402 5 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeder 3 . Active uncontrolled infection 4 . Prior chemotherapy , radiation therapy , immunotherapy within 4 week 5 . Serious uncured wound 6 . Active uncontrolled malignancy 7 . Steroids immunosuppressing agent dependent status 8 . Interstitial pneumonia 9 . Ileus 10 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Epitope peptide</keyword>
	<keyword>CTL</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Vaccination VEGFR1</keyword>
	<keyword>VEGFR2</keyword>
</DOC>